The group's principal activity is to develop and commercialize clinical compounds and core technologies for the life sciences. the group is in the development stage. the group uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. the group focuses its development efforts on several kinace leads in the areas of oncology, metabolism and immunology. the group recently obtained the exclusive worldwide rights to a novel technology, which is called small integrated building-blocks (sib) for the conversion of peptides and other existing drugs into small molecules that have the potential for oral delivery. in addition to developing drug candidates with the kinace platform, the group has been developing sulodexide, or krx-101, to which it has an exclusive license in north america, japan and other markets.